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Abstract: OBJECTIVES Data from randomized controlled trials have shown the feasibility of discon-
tinuation of bDMARD therapy in patients with RA that have reached remission. Criteria for selecting
patients that are likely to remain in remission are still incompletely defined.We aimed to identify pre-
dictors of successful discontinuation of bDMARD therapy in the Swiss Clinical Quality Management
(SCQM) registry, a real-world cohort of RA patients. METHODS RA patients in DAS28-ESR remission
who stopped bDMARD/tsDMARD treatment were included. Loss of remission was defined as a DAS28-
ESR > 2.6 or restart of a bDMARD/tsDMARD. Time to loss of remission was the main outcome.
Kaplan-Meier methods were applied and cox regression was used for multivariable analyses adjusting for
confounding factors. Missing data were imputed using multiple imputation. RESULTS 318 patients in
a bDMARD/tsDMARD-free remission were followed between 1997 and 2017. 241 patients (76%) lost
remission after a median time of 0.9 years (95%CI 0.7-1.0). The time to loss of remission was shorter in
women, in patients with a longer disease duration >4yrs and in patients who did not meet CDAI remis-
sion criteria at baseline. Remission was longer in patients with csDMARD therapy during b/tsDMARD
free remission (HR 0.8, p= 0.05, 95%CI 0.6-1.0). CONCLUSION In a real-world patient population the
majority of patients who discontinued b/tsDMARD treatment lost remission within <1 year. Our study
confirms that fulfilment of more rigorous remission criteria and csDMARD treatment increases the chance
of maintaining b/tsDMARD free remission.
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Objectives: Data from randomized controlled trials have shown the feasibility of discontinuation of 
bDMARD therapy in patients with RA that have reached remission. Criteria for selecting patients that 
are likely to remain in remission are still incompletely defined. 
We aimed to identify predictors of successful discontinuation of bDMARD therapy in the Swiss 
Clinical Quality Management (SCQM) registry, a real-world cohort of RA patients.
Methods: RA patients in DAS28-ESR remission who stopped bDMARD/tsDMARD treatment were 
included. Loss of remission was defined as a DAS28-ESR>2.6 or restart of a bDMARD/tsDMARD. Time 
to loss of remission was the main outcome. Kaplan-Meier methods were applied and cox regression 
was used for multivariable analyses adjusting for confounding factors. Missing data were imputed 
using multiple imputation. 
Results: 318 patients in a bDMARD/tsDMARD-free remission were followed between 1997 and 2017. 
241 patients (76%) lost remission after a median time of 0.9 years (95%CI 0.7-1.0). The time to loss of 
remission was shorter in women, in patients with a longer disease duration >4yrs and in patients who 
did not meet CDAI remission criteria at baseline. Remission was longer in patients with csDMARD 
therapy during b/tsDMARD free remission (HR 0.8, p=0.05, 95%CI 0.6-1.0). 
Conclusion: In a real-world patient population the majority of patients who discontinued b/tsDMARD 
treatment lost remission within less than 1 year. Our study confirms that fulfilment of more rigorous 
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Key messages: 
- Remission is lost in RA patients less than one year after discontinuation of 
bDMARD/tsDMARD therapy. 
- Discontinuation of bDMARD/tsDMARD treatment should be considered for patients with 
short disease duration who fulfil stringent CDAI remission criteria.
- Maintenance of csDMARDs increases the duration of remission without bDMARD/tsDMARDs.
Introduction
Early treatment with tight control and treat-to-target approaches and the introduction of biologic 
disease modifying anti-rheumatic drugs (bDMARD) substantially improved the therapeutic options in 
RA. Combination therapy of bDMARD with methotrexate was shown to potently suppress 
inflammation and erosive joint destruction and remission became achievable in up to 75% of patients 
(1). With an increasing population of patients in long-term remission, tapering or discontinuing DMARD 
therapy, in particular biologics, has become a focus of clinical research in RA. In patients with sustained 
remission bDMARD tapering is proposed by the current EULAR and ACR recommendations (2, 3) in 
order to minimize the risk of side effects and for economic reasons (4-6). Data from randomized 
controlled trials have shown that in patients with sustained remission tapering of DMARD therapy is 
feasible (7), however discontinuation of bDMARDs was associated with an increased risk of losing 
remission or low disease activity (LDA, defined as DAS28-ESR ≥2.6 and ≤3.2) and radiographic 
progression (8). Nevertheless, an important percentage of patients retained remission after 
discontinuation of biologics in randomized controlled trials. Several studies have reported factors 
predicting maintenance of remission after discontinuation of bDMARD.  In a recent systematic 
literature review low disease activity, better physical function, absence of rheumatoid factor and ACPA 
and low CRP/ESR were described, however due to a great heterogeneity of the studies no firm 










































































































discontinuation of bDMARDs. In particular, there is a lack of observational data from large patient 
cohorts with longer follow up. We therefore aimed to analyse patients in remission in a large 
prospective cohort study under real-world conditions, to define predictors for maintenance of 











































































































Study design and patients
This study is based on the multicenter, longitudinal RA cohort of the Swiss Clinical Quality Management 
in Rheumatic Diseases (SCQM-RA). SCQM-RA has been described in detail previously (10). Patients 
included in the registry are evaluated at regular intervals for disease activity, patient reported 
outcomes and DMARD therapy. All patients enrolled in SCQM have provided a written informed 
consent. The study was approved by the responsible ethics review board, EKNZ (2020-00018). 
In this analysis, we included patients with RA, as diagnosed by the treating rheumatologist, who had 
stopped treatment with a bDMARD or tsDMARD between June 2001 and December 2017 and were 
thereafter in remission. For simplicity bDMARDs and tsDMARDs are referred to as bDMARDs. 
Remission was defined by a disease activity score based on 28 joints using the erythrocyte 
sedimentation rate (DAS28-ESR) below or equal to 2.6. To be included in this study, patients were 
required to have a clinical visit with a DAS28-ESR≤2.6 within a period of 90 days before, or 30 days 
after bDMARD discontinuation and at least one follow-up visit after the stop of the bDMARD.  
Patients on rituximab were excluded because of the long and varying dosing intervals, which do not 
allow to define bDMARD free remission time. We did, however, include patients on tsDMARDs because 
of their efficacy profile comparable to bDMARDs (only tofacitinib being approved in Switzerland during 
the study period).      
To exclude patients with short interruptions of therapy for other reasons, we defined a minimal time 
after discontinuation of the bDMARD until a visit with a DAS28-ESR flare or reintroduction of a 
bDMARD. The definition of this minimal period was determined as multiples of the dosing interval of 
each bDMARD. For abatacept and tocilizumab we defined this period to be 60 days for i.v. and 30 days 
for s.c. administration, for adalimumab and certolizumab 42 days, for etanercept 30 days, for 
golimumab 60 days, for infliximab 90 days and for tofacitinib 14 days. 
Conventional synthetic DMARD (csDMARD) was defined as therapy with methotrexate or leflunomide. 










































































































hydroxychloroquine and sulfasalazine combination (n=2) was not considered as csDMARD therapy for 
our analysis.
Patients were included regardless of the reason for discontinuation of the bDMARD recorded in the 
databank. Remission was indicated as reason for discontinuation in 28%, adverse events in 27% and 
ineffectiveness of bDMARD in 15%,  for 10% of patients the reason was missing. To exclude the 
possibility, that patients could have been misclassified by our selection criteria, we also analyzed a 
population that excluded all patients for whom insufficient treatment response had been indicated as 
a reason for discontinuation of bDMARD treatment.
Outcomes
The main outcome of this study was the time between discontinuation of the bDMARD and the loss of 
remission. Loss of remission was defined as either a DAS28-ESR above 2.6 or the reintroduction of 
therapy with a bDMARD. Time in remission was defined as the time between the stop of the bDMARD 
of interest until loss of remission or until the patient was censored (at the last visit in SCQM).
Explanatory variables
The association of patient characteristics and disease related factors at the time of bDMARD 
discontinuation (“baseline”) with the time in bDMARD-free remission was analysed. We analysed the 
following patient characteristics and disease related factors: age and smoking status, disease duration 
defined as the time from the first symptoms to inclusion in the study, the presence of rheumatoid 
factor (RF) and anti-citrullinated protein antibodies (ACPA) , disease activity as measured by DAS28-
ESR, clinical disease activity index (CDAI), simplified disease activity index (SDAI) and RA disease activity 
index (RADAI5), health assessment questionnaire (HAQ) score, concomitant treatment with 
methotrexate or leflunomide (csDMARD) at any time during bDMARD-free remission, the number of 











































































































Frequencies/percentages or median/interquartile ranges (IQR) were calculated. Kaplan-Meier 
methods were applied to univariately assess associations of patient characteristics and disease related 
factors with the time in remission after bDMARD discontinuation. 
Cox proportional hazards regression analysis was applied to multivariably combine the a priori 
defined possible risk factors of loss of remission. The disease related factors as described above were 
included in the multivariable model. Missing baseline values were imputed using multiple imputation 
with chained equations (m = 50) using Stata’s inbuilt mi command. Continuous data were modelled 
using predictive mean matching and categorical data were modelled by logistic regression in the 
imputation model (11-13). For composite scores such as the DAS28-ESR, CDAI and SDAI the 
components of the scores were imputed. All (multivariable) regression results in this paper are based 
on the imputed data (the results obtained from the complete case analyses are provided as 












































































































Of the total 9625 RA patients in the SCQM registry, 318 patients fulfilled the inclusion criteria. Of these 
83% were women and the median age was 58 years (Table 1). The median disease duration was 7.5 
years. Most of the patients discontinued a TNFα-inhibitor (76%) and in 68% it was the first bDMARD 
the patients were ever treated with. The median observation time of all 318 patients was 2.8 years 
(IQR 1.2-4.9). In our cohort no patients had a disease duration shorter than 1.3 years and only a small 
number of patients (n=19) had a disease duration ≤ 2 years. At the moment of bDMARD withdrawal, 
59% of patients had a concomitant treatment with methotrexate or leflunomide. 145 patients (46%) 
were treated with methotrexate and or leflunomide during the whole time of bDMARD-free remission, 
whereas 36% of the patients never received methotrexate or leflunomide during bDMARD free 
remission (Table 1).
Of the included patients 24% remained in remission, with a mean observation time of 2.1 years (SD 
2.3) and a median observation time of 1.2 years (IQR 0.7; 2.9). 241 patients (76%) lost remission after 
bDMARD discontinuation during follow up. Of those 54% fulfilled the criteria of loss of remission by re-
starting a bDMARD, 34% by experiencing a DAS28-ESR flare above 2.6 and 12% fulfilled both criteria. 
The median time in remission was 0.9 years (95%CI 0.7-1.0). Within the first year after bDMARD 
discontinuation already 54% of patients had lost remission. In 42% the same bDMARD was restarted. 
Female patients lost remission faster than male patients (Figure 1A; HR 1.5, 95CI 1.1-2.1, p=0.005). 
This was also seen after adjusting for other covariates (Figure 2; HR 1.4, 95%CI 1.0-2.0, p=0.04). Age 
and ACPA or RF status had no impact on the time in bDMARD-free remission, neither in the univariate 
(Age: hazard ratio [HR] 1.00, 95%CI 1.0 – 1.0, p=0.76, ACPA: HR 1.19, 95%CI 0.9 – 1.6, p=0.26, RF: HR 
1.04, 95%CI 0.8 – 1.4, p=0.77) nor in multivariate cox regression analyses (Figure 2). Also, smoking was 
not associated with a shorter time in remission in the univariate analysis (HR 0.96, 95%CI 0.8 – 1.2, 
p=0.7). We analyzed the association of disease duration with the time in remission in quartiles and 
found a significant correlation (1st quartile: disease duration ≤3.9yrs, 2nd quartile: >3.9 to ≤7.5yrs, 3rd 










































































































loss of remission (Figure 1B; p=0.03. In univariate analysis HR[2nd quartile] 1.4, 95%CI 0.9-2.0, p=0.1, 
HR[3rd quartile] 1.7, 95%CI 1.2-2.5, p=0.005, HR[4th quartile] 1.5, 95%CI 1.1-2.2, p=0.03 vs 1st quartile). 
Also in multivariate analysis the inverse association of disease duration and time on remission was 
seen (Figure 2; HR[2nd quartile] 1.6, 95%CI 1.0 – 2.3, p=0.03, HR[3rd quartile] 1.7, 95%CI 1.1 – 2.4, 
p=0.01, HR[4th quartile] 1.5, 95%CI 1.0 – 2.3, p=0.05 vs 1st quartile).
 In patients who were not in remission defined by the CDAI at baseline (CDAI ≤2.8), there was a 
tendency for a faster loss of remission (Figure 1C; univariate cox regression: HR [CDAI low disease 
activity = CDAI >2.8-10] 1.2, 95%CI 0.7-1.9, p=0.5, HR [CDAI moderate/high disease activity = CDAI >10] 
1.3, 95%CI 0.7-2.5,p=0.4, both vs CDAI remission). This association became significant in multivariate 
analysis (HR [CDAI low disease activity] 1.6, 95%CI 1.1 – 2.4, p=0.02, HR [CDAI moderate/high disease 
activity] 2.4, 1.4 – 4.2, p=0.002, both vs CDAI remission; Figure 2). In the univariate regression there 
was no significant association between bDMARD-free remission and DAS28-ESR (HR 1.1, 95%CI 0.9 – 
1.4, p=0.5), SDAI (HR 1.0, 95%CI 1.0 – 1.0, p=0.9), RADAI5 scores (HR 1.1, 95%CI 1.0 – 1.2, p=0.02) or 
HAQ (HR 1.2, 95%CI 0.9 – 1.6, p=0.1). The univariate regression analysis of the number of different 
bDMARD agents prior to the discontinuation of the bDMARD suggested an elevated risk to loose 
remission, after exposure to at least 3 prior bDMARDs (HR 1.8, 95%CI 1.0 – 3.1, p=0.051).  In addition, 
therapy with tocilizumab, abatacept or tofacitinib as a group compared to TNFα-inhibitors showed a 
higher risk for loss of remission (HR 1.3, 95%CI 1.0-1.8, p=0.05), these trends however were not 
confirmed in multivariate analyses, neither for the numbers of bDMARDs before (Figure 2; HR 1.2, 
95%CI 0.6 – 2.2, p=0.6) nor for bDMARD type (Figure 2; HR 1.1, 95%CI 0.8-1.5, p=0.7). No differences 
were found between tocilizumab (HR 1.1, 95%CI 0.7-1.7, p=0.6) and abatacept (HR 0.8, 95%CI 0.4-1.4, 
p=0.4) versus TNF-Inhibitors. Tofacitinib showed a significantly increased hazard ratio for loss of 
remission (HR 2.1, 95%CI 1.0-4.1, p=0.04). However the patient number, who were treated with 










































































































Patients who received methotrexate and or leflunomide during the observation period had a lower 
risk for loss of remission in the univariate analysis than those without csDMARD therapy (Figure 1D; 
HR 0.7, p=0.006). This was also significant in the multivariate analysis (Figure 2; HR 0.8, 95%CI 0.6 – 
1.0, p=0.05).
The patients were included for analysis regardless of the reason to stop the bDMARD as long as 
patients fulfilled the criteria of remission as detailed above. The reason for discontinuation was 
available in the database for 286 patients (89.9%). For 48 of those patients ineffectiveness was 
indicated as one of the reasons for discontinuation of the bDMARD therapy (reasons for 
discontinuation are shown in Supplementary Table 1). To take into account the possibility of patients 
failing bDMARDs being misclassified as patients in remission, we performed a subgroup analysis in 
which we excluded the patients with ineffectiveness as reason of the bDMARD discontinuation 
(Supplementary Table 2). The results of this subgroup (n=270) were comparable, with the same 
parameters showing an association with the time in remission, except that there was no significant 
difference between patients with disease duration >13yrs (4th quartile) and ≤4yrs (1st quartile) in the 
multivariate analysis (Supplementary Figures S1, S2). 
The results of the multivariable regression analyses shown in Figure 2 and supplementary Figure S2 
are based on the imputed data, the respective results of a complete case analysis are shown in 
supplementary Figure S3.
Discussion
We have studied bDMARD free remission in patients who had stopped bDMARDs or tsDMARDs in the 
large prospective real-world cohort SCQM. In our cohort the large majority (76%) of the patients lost 
remission after a median of 9 months. However, 24% of the patients maintained remission with a 
median follow up of 1.2 years. This is less than reported in randomized controlled trials or 










































































































remission discontinuing infliximab remained in DAS28 remission at 12 months (19). In the PRIZE 
study the rate of patients in sustained remission at 24 and 39 weeks after discontinuation of 
etanercept was 40%, in patients who also discontinued therapy with methotrexate only 23% 
remained in remission (17). In a substudy of the BeSt study 52% of the patients remained in LDAS, in 
48% therapy with infliximab had to be restarted after a median of 17 months (20). The randomized 
controlled trial RETRO reported similar numbers with 52% relapses within 12 months in a study arm 
with 6 months dose reduction of bDMARD and csDMARD followed by discontinuation of all DMARD 
therapy (21). The lower percentage of patients that remained in remission after bDMARD 
discontinuation found in our study may be due to the longer follow up. A recent observational study 
has shown that relapse rates after tapering biologics in a real-life setting increased over time after 12 
months (22). In our study the mean disease duration was 7.5 years which is longer than in most of 
the trials published so far. In fact, disease duration was inversely correlated with the time in 
bDMARD free remission in our cohort. An association of successful cessation of TNF-inhibitor therapy 
with a shorter symptom duration until treatment start in RA patients has previously been shown in a 
small study (23). Similarly, in the HONOR study an association of longer disease duration with a loss 
of remission after discontinuation of adalimumab was shown (19). In addition, a disease duration of 
>10 years was reported to be associated with a shorter time to relapse in an open label randomized 
controlled trial of stopping vs continuing therapy with TNF-inhibitors (24).
Whereas DAS28 itself was not an independent predictor of maintenance of remission in our study, 
CDAI low, moderate or high disease activity as opposed to CDAI remission at the time of bMDARD 
discontinuation was significantly associated with a faster loss of remission. This result is in agreement 
with the HONOR study that reported “deep” remission with a DAS28<2.0 being a predictor for 
maintenance of remission (19). In the RETRO study DAS28 was predictive for remaining in remission, 
however in that study the median DAS28 at baseline was well below 2.0 (21). Our data suggest that 
the more stringent remission criteria defined by CDAI rather than DAS28 remission should be 










































































































Another predictor for a shorter time in remission was the absence of a csDMARD therapy. Patients 
with either methotrexate or leflunomide therapy had a significantly higher chance to remain in 
remission. In the PRIZE study the remission rates in the patients in the methotrexate arm dropped 
significantly after discontinuation of methotrexate at week 39 (17). Similarly, in the RETRO study the 
relapse rates were the highest in the group that stopped all DMARD therapy (21).  Our data supports 
to continue csDMARD therapy in patients that stop bDMARD therapy in sustained remission.
Function as assessed by HAQ was not found to be associated with time in bDMARD free remission in 
our study. In contrast, HAQ at baseline was reported to be associated with the risk of flares  in a step 
down strategy of TNF inhibitor therapy (14). Low HAQ was also a predictor for restarting therapy in 
DMARD free remission in an exploratory analysis of the BeSt study  (25). In addition, a Japanese study 
found that a lower HAQ-DI was a predictor for maintenance of remission or LDA after discontinuation 
of therapy with abatacept (26). 
Dose reduction and discontinuation of bDMARD treatment has been studied for a variety of 
bDMARDs, including the TNF inhibitors etanercept, infliximab, adalimumab, certolizumab pegol as 
well as abatacept and tocilizumab (8). However, no direct comparisons have been published. In our 
analysis we did not observe significant differences of the time in bDMARD free remission between 
patients with previous TNF inhibitor therapy and patients with abatacept or tocilizumab treatment. 
Patients who discontinued the JAK inhibitor tofacitinib tended to have an increased hazard ratio for a 
shorter time in bDMARD free remission, however the patient number was too small to draw any 
conclusions. Further studies are needed with larger patient populations to analyse potential 
differences of the risk of losing remission for the individual bDMARDs.  This is important as also the 
predictors for loss of remission may differ between different bDMARDs, e.g. in a recent study low IL-











































































































Interestingly, we found that female sex was significantly associated with a shorter time of bDMARD 
free remission, after adjusting for differences in baseline characteristics. A recent systematic 
literature review found 4 studies with baseline characteristics and information on successful or 
unsuccessful discontinuation of bDMARDs. Patients who did not relapse were more often female (9). 
However, there are no reports of gender as an independent predictor of successful bDMARD 
discontinuation.
The strengths of our study are the real-life setting, a relatively large number of patients and a longer 
follow up than most of the published randomized trials.  Limitations are the observational nature of 
this prospective cohort study. The decision to stop bDMARD treatment was at the discretion of the 
treating rheumatologist, which could introduce an indication bias. Disease flares in between visits 
may have been missed, although this also applies to randomized studies.
In summary, our study provides information on predictors for successful discontinuation of bDMARD 
therapy in patients with RA in remission in a real-world setting. Our findings confirm and extend 
previous results from randomized controlled studies and suggest that bDMARD discontinuation 
should be considered primarily in patients with a disease duration <4 years, fulfilling CDAI remission 
criteria and continuing csDMARD therapy. 
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Table 1. Demographic and disease characteristics of patients with bDMARD-free remission at the 
time of bDMARD discontinuation
Characeristics Median (IQR) or %
Sex n=318 female 74
Age n=318 57.5 (46.2-66.0)
Smoking n=155 never 45
former 26
current 29
Disease duration in years n=312 7.5 (3.9-12.6)




Number of previous n=318 0 68
bDMARDs 1 to 2 27
≥3 5
Concomittant csDMARD n=318 64
ACPA positive n=261 64
RF positive n=306 72
DAS28-ESR n=318 2 (1.5-2.3)










RADAI5 n=219 2.4 (1.2-4)
HAQ n=228 0.4 (0-1)
*at any time during bDMARD-free remission. ACPA: Anti citrullinated peptide/protein, bDMARD: 
biologic disease-modifying antirheumatic drug, CDAI: clinical disease activity index, DAS28-ESR: 
disease activity score 28, HAQ: The health assessment questionnaire, RADAI5: Rheumatoid disease 
activity index-5, RF: Rheumatoid factor, SDAI: simplified disease activity index, csDMARD: 











































































































Figure 1: Kaplan-Meier curves for time in bDMARD-free remission according to different risk 
factors. Cumulative percentage of patients in bDMARD-free remission over time are shown according 
to sex (A), disease duration shown in quartiles (1st quartile: ≤3.9 years, 2nd quartile: >3.9 to ≤7.5 
years, 3rd quartile >7.5 to ≤ 12.6 years, 4th quartile: >12.6 years) (B), CDAI Score (C) and concomitant 
csDMARD therapy during bDMARD-free remission (D). 
Figure 2: Multivariate cox regression analysis with impact on time in bDMARD-free remission 
1Disease duration in years, 2nd quartile (>3.9 to ≤7.5 years) vs 1st quartile (≤3.9 years, reference), 23rd 
quartile (>7.5 to ≤ 12.6 years) vs 1st quartile, 34th quartile (>12.6 years) vs 1st quartile, 4vs. CDAI 
remission.
Abbreviations  
ACPA anti-citrullinated protein antibodies 
bDMARD biological disease-modyfinging antirheumatic drugs
CDAI Clinical disease activity index
CI Confidence Intervall 
csDMARD conventional synthetic disease-modifying antirheumatic drug
DAS28-ESR Disease Activity Score 28
HAQ Health Assessment Questionnaire 
HR Hazard Ratio
IQR Interquartile range
RA Rheumatoid Arthritis 
RADAI5 rheumatoid arthritis disease activity index 5
RAU Ratingen Score
RF rheumatoid factor
SCQM Swiss clinical quality management in rheumatic diseases registry 










































































































tsDMARD targeted synthetic disease-modifying antirheumatic drug
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Supplementary Table 1. Reasons for discontinuation of the bDMARD as selected by the
rheumatologists from the options: remission, ineffectiveness, adverse event, other.
Reason for bDMARD discontinuation N (%)
Remission1 89 (28)
Ineffectiveness 48 (15)
Adverse event2 85 (27)
Other 64 (20)
Missing 32 (10)
1 Including: remission, remission and other, remission and adverse event
2 Including: adverse event, adverse event and other
Supplementary Table 2. Demographic and disease characteristics of patients with bDMARD-free remission 
at the time of bDMARD discontinuation (patients excluded with ineffectiveness as reason for 
discontinuation). 
Characeristics Median (IQR) or %
Sex n=270 female 72
Age n=270 58 (46-66)
Smoking n=129 never 50
former 25
current 25
Disease duration in years n=262 6.2 (3.4-11.5)




Number of previous n=270 0 69
bDMARDs 1 to 2 26
≥3 5
Concomittant csDMARD n=270 63
ACPA positive n=222 64
RF positive n=260 72
DAS28-ESR n=270 1.9 (1.5-2.3









RADAI5 n=191 2 (1-3.6)









































































































Legends of supplementary Figures:
Supplementary Figure S1: Kaplan-Meier curves for time in bDMARD-free remission according to different 
risk factors (patients excluded with ineffectiveness as reason for discontinuation). Cumulative percentage of 
patients in bDMARD-free remission over time are shown according to sex (A), disease duration shown in 
quartiles (1st quartile: ≤3.9 years, 2nd quartile: >3.9 to ≤7.4 years, 3rd quartile >7.4 to ≤ 12.6 years, 4th quartile: 
>12.6 years) (B), CDAI Score (C) and concomitant csDMARD therapy during biologic-free remission (D). 
Supplementary Figure S2: Multivariate cox regression analysis with impact on time in bDMARD-free 
remission (patients excluded with ineffectiveness as reason for discontinuation). 1Disease duration in years, 
2nd quartile (>3.9 to ≤7.5 years) vs. 1st quartile (≤3.9 years, reference), 23rd quartile (>7.4 to ≤ 12.6 years) vs. 1st 
quartile, 34th quartile (>12.6 years) vs. 1st quartile), 4vs. CDAI remission, ACPA: Anti citrullinated protein 
antibodies, bDMARD: biological disease-modifying antirheumatic drug, CDAI: clinical disease activity index, 
DAS28-ESR: disease activity score 28, RF: Rheumatoid factor, csDMARD: conventional disease-modifying 
antirheumatic drug
Supplementary Figure S3: Multivariate cox regression analysis with impact on time in bDMARD-free 
remission. (complete case analysis). 1Disease duration in years, 2nd quartile (>3.9 to ≤7.5 years) vs. 1st quartile 
(≤3.9 years, reference), 23rd quartile (>7.5 to ≤ 12.6 years) vs. 1st quartile, 34th quartile (>12.6 years) vs. 1st 
quartile, 4vs. CDAI remission, ACPA: Anti citrullinated protein antibodies, bDMARD: biological disease-
modifying antirheumatic drugs, CDAI: clinical disease activity index, DAS28-ESR: disease activity score 28, RF: 
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